NASDAQ:HBIO

Harvard Bioscience (HBIO) Stock Price, News & Analysis

$3.69
-0.03 (-0.81%)
(As of 04/24/2024 ET)
Today's Range
$3.67
$3.75
50-Day Range
$3.69
$4.86
52-Week Range
$3.60
$6.29
Volume
63,555 shs
Average Volume
85,308 shs
Market Capitalization
$160.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Harvard Bioscience MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
89.7% Upside
$7.00 Price Target
Short Interest
Healthy
1.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.18
Upright™ Environmental Score
News Sentiment
0.15mentions of Harvard Bioscience in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.98 out of 5 stars

Computer And Technology Sector

298th out of 586 stocks

Analytical Instruments Industry

10th out of 26 stocks

HBIO stock logo

About Harvard Bioscience Stock (NASDAQ:HBIO)

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

HBIO Stock Price History

HBIO Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Harvard man pleads guilty to assault
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Harvard’s applications drop amid campus scandals
See More Headlines
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CUSIP
41690610
Employees
391
Year Founded
1901

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+89.7%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-3,410,000.00
Pretax Margin
-2.28%

Debt

Sales & Book Value

Annual Sales
$112.25 million
Cash Flow
$0.23 per share
Book Value
$1.71 per share

Miscellaneous

Free Float
39,493,000
Market Cap
$160.14 million
Optionable
Optionable
Beta
1.42

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

HBIO Stock Analysis - Frequently Asked Questions

What is Harvard Bioscience's stock price target for 2024?

0 brokers have issued 12 month price objectives for Harvard Bioscience's shares. Their HBIO share price targets range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 89.7% from the stock's current price.
View analysts price targets for HBIO
or view top-rated stocks among Wall Street analysts.

How have HBIO shares performed in 2024?

Harvard Bioscience's stock was trading at $5.35 at the start of the year. Since then, HBIO shares have decreased by 31.0% and is now trading at $3.69.
View the best growth stocks for 2024 here
.

Are investors shorting Harvard Bioscience?

Harvard Bioscience saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 636,700 shares, a decrease of 11.1% from the March 15th total of 716,600 shares. Based on an average daily trading volume, of 83,500 shares, the short-interest ratio is currently 7.6 days.
View Harvard Bioscience's Short Interest
.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) posted its earnings results on Thursday, March, 7th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.02. The medical instruments supplier earned $28.15 million during the quarter, compared to analyst estimates of $27.80 million. Harvard Bioscience had a negative net margin of 3.04% and a positive trailing twelve-month return on equity of 2.75%.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

How do I buy shares of Harvard Bioscience?

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Harvard Bioscience have any subsidiaries?
The following companies are subsidiares of Harvard Bioscience: Data Sciences International.
Read More
This page (NASDAQ:HBIO) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners